Related Experiment Video
Updated: Aug 26, 2025
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
Initial sirolimus dosage recommendations for pediatric patients with PIK3CD mutation-related immunodeficiency disease
Xiao Chen1, Jinglin Wang2, Jianger Lan1
1Department of Pharmacy, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.
Insights
This study determined initial sirolimus dosages for children with PIK3CD immunodeficiency. Dosages vary by weight and if posaconazole is used, aiding personalized treatment.
Area of Science:
- Pharmacology
- Immunology
- Genetics
Background:
- Sirolimus treats PIK3CD mutation-related immunodeficiency in children.
- Optimal initial sirolimus dosing for this pediatric population is currently undefined.
Purpose of the Study:
- To establish initial sirolimus dosage recommendations for pediatric patients with PIK3CD mutation-related immunodeficiency.
- To provide a reference for individualized clinical drug administration in this patient group.
Main Methods:
- Population pharmacokinetic (PPK) modeling was employed.
- Monte Carlo simulations were used to analyze pediatric patient data.
- Body weight and concurrent posaconazole use were key factors in the PPK model.
Main Results:
- Sirolimus clearance is significantly reduced (1:0.238 ratio) in children taking posaconazole compared to those not on the medication.
- Recommended initial sirolimus dosages without posaconazole range from 0.04-0.07 mg/kg/day based on weight (10-60 kg).
- Recommended initial sirolimus dosage with posaconazole is 0.02 mg/kg/day for all weights (10-60 kg).
Conclusions:
- This study presents the first sirolimus PPK model for recommending initial dosages in children with PIK3CD immunodeficiency.
- The findings offer crucial guidance for tailoring sirolimus therapy in pediatric patients.
- Individualized dosing strategies are essential for effective management of this rare immunodeficiency.
Abstract:
Sirolimus is used to treat pediatric patients with PIK3CD mutation-related immunodeficiency disease. However, the initial dosages of sirolimus remain undecided. The present study aims to explore initial dosages in pediatric patients with PIK3CD mutation-related immunodeficiency disease. Pediatric patients with this disease were analyzed using the population pharmacokinetic (PPK) model and the Monte Carlo simulation. Body weight and concomitant use of posaconazole were included in the final PPK model, where, under the same weight, clearances of sirolimus were 1 : 0.238 between children without and children with posaconazole. Without posaconazole, the initial dosages of sirolimus were 0.07, 0.06, 0.05, and 0.04 mg/kg/day for body weights of 10-14, 14-25, 25-50, and 50-60 kg, respectively. With posaconazole, the initial dosages of sirolimus were 0.02 mg/kg/day for body weights of 10-60 kg. This is the first attempt to build a sirolimus PPK model for recommending initial dosages in children with PIK3CD mutation-related immunodeficiency disease, thereby providing a reference for individualized clinical drug administration.
